The hunt for neutralising antibodies against SARS-CoV-2

Scientists hope that a legacy of the novel coronavirus in recovered COVID-19 patients – antibodies in their blood – could lead to drugs to treat others. The Merten group at EMBL Heidelberg has pivoted its microfluidics platform to support the search for neutralising antibodies that could…

By Adam Gristwood


Miniature testing of drug pairs on tumour biopsies

Combinations of cancer drugs can be quickly and cheaply tested using a novel microfluidic device…

By Emma Steer


EMBL spinoff Velabs Therapeutics to help antibody discovery. IMAGE: Velabs Therapeutics

EMBL spinoff to help antibody discovery

New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic antibodies…

By Iris Kruijen

Lab Matters

Sorting out HIV

An EMBL collaboration devises a new method that could speed up vaccine development for HIV…

By Edward Dadswell


First, find your membrane

Collaboration between scientists reveals collaboration between lipids.…

By Sonia Furtado Neves


Sense of space

EMBL scientists demonstrate that spatial constraints are a key factor in determining nucleus size.…

By Isabelle Kling



Read the latest Issues of our magazine - EMBLetc.

Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.

EMBLetc. archive